Vertex finishes zimislecel manufacturing analysis and resumes dosing

Vertex Pharmaceuticals/Zimislecel

Vertex said in its first-quarter 2026 results that it had completed the internal manufacturing analysis for the Phase 1/2/3 study of zimislecel, its stem-cell islet therapy for type 1 diabetes, and had resumed dosing. The company says multiple patients have been treated since dosing restarted.

• The release says Vertex completed the internal manufacturing analysis and resumed dosing, but does not say on what date dosing restarted.
• Vertex expects to give updated timelines for completing the study later in 2026.
• The release gives no new date for regulatory submissions.